Concepedia

Publication | Open Access

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

DOIFull Paper Access

405

Citations

22

References

2009

Year

Claus M. Larsen, Mirjam Faulenbach, Allan Vaag, Jan A. Ehses, Marc Y. Donath, Thomas Mandrup‐Poulsen
Diabetes Care

Abstract

IL-1 blockade with anakinra induces improvement of the PI/I ratio and markers of systemic inflammation lasting 39 weeks after treatment withdrawal.

References

YearCitations

Page 1